Herantis Pharma Oyj Stock Current Valuation
| HRTIS Stock | EUR 1.49 0.07 4.49% |
Valuation analysis of Herantis Pharma Oyj helps investors to measure Herantis Pharma's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Herantis Pharma's price fluctuation is dangerous at this time. Calculation of the real value of Herantis Pharma Oyj is based on 3 months time horizon. Increasing Herantis Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Herantis Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Herantis Stock. However, Herantis Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.49 | Real 1.23 | Hype 1.49 |
The intrinsic value of Herantis Pharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Herantis Pharma's stock price.
Estimating the potential upside or downside of Herantis Pharma Oyj helps investors to forecast how Herantis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Herantis Pharma more accurately as focusing exclusively on Herantis Pharma's fundamentals will not take into account other important factors: Herantis Pharma Oyj Company Current Valuation Analysis
Herantis Pharma's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Herantis Pharma Current Valuation | 25.86 M |
Most of Herantis Pharma's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Herantis Pharma Oyj is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Herantis Pharma Oyj has a Current Valuation of 25.86 M. This is 99.82% lower than that of the Pharmaceuticals sector and 99.44% lower than that of the Health Care industry. The current valuation for all Finland stocks is 99.84% higher than that of the company.
Herantis Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Herantis Pharma's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Herantis Pharma could also be used in its relative valuation, which is a method of valuing Herantis Pharma by comparing valuation metrics of similar companies.Herantis Pharma is currently under evaluation in current valuation category among its peers.
Herantis Fundamentals
| Return On Equity | -13.37 | |||
| Return On Asset | -0.6 | |||
| Current Valuation | 25.86 M | |||
| Shares Outstanding | 16.91 M | |||
| Shares Owned By Insiders | 31.52 % | |||
| Shares Owned By Institutions | 32.60 % | |||
| Price To Earning | (7.20) X | |||
| Price To Book | 15.17 X | |||
| Gross Profit | 90 K | |||
| EBITDA | (9.74 M) | |||
| Net Income | (12.77 M) | |||
| Cash And Equivalents | 7.86 M | |||
| Cash Per Share | 0.81 X | |||
| Total Debt | 6.29 M | |||
| Debt To Equity | 0.95 % | |||
| Current Ratio | 1.54 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (9.93 M) | |||
| Earnings Per Share | (1.25) X | |||
| Target Price | 2.1 | |||
| Number Of Employees | 13 | |||
| Beta | 0.51 | |||
| Market Capitalization | 39.58 M | |||
| Total Asset | 7.76 M | |||
| Retained Earnings | (27 M) | |||
| Working Capital | 5 M | |||
| Current Asset | 6 M | |||
| Current Liabilities | 1000 K | |||
| Z Score | -3.9 | |||
| Net Asset | 7.76 M |
About Herantis Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Herantis Pharma Oyj's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Herantis Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Herantis Pharma Oyj based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Herantis Stock
Herantis Pharma financial ratios help investors to determine whether Herantis Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Herantis with respect to the benefits of owning Herantis Pharma security.